Want to join the conversation?
$GSK will pay $317MM for late-stage asset that includes fostemsavir (BMS-663068), an attachment inhibitor, currently in phase III development for heavily treatment experienced patients. $GSK will pay $33MM for purchase of preclinical and discovery stage research assets that includes a novel biologic (BMS-986197) with a triple mechanism of action.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?